Journals / Türk Biyokimya Dergisi / 2020 / Cilt: 45 - Sayı: 3

The effect of specific therapeutic agentson inflammation in sepsis-induced neonatal rats

Sepsis oluşturulmuş neonatal sıçanlarda spesifik terapötik ajanların inflamasyon üzerindeki etkisi

Pages
315–321
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In Western Blot evaluations, there was a significant decrease in the expression of NF-κB protein in treatment groups compared to sepsis group.Conclusions: It was observed that Thalidomide and Etanercept had potential effects on the treatment of neonatal sepsis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to investigate the effect of Thalidomide and Etanercept on inflammation parameters in a neonatal rat sepsis model induced with Lipopolysaccharide (LPS).Materials and methods: Four-week-old male Wistar Albino rats were used in the experiment.
📊
Key Findings & Data:LPS (5 mg/kg) was administered to rats as sepsis-inducing agent and two anti-inflammatory drugs, Thalidomide and Etanercept were given intraperitoneally as chemotherapeutic agents.
💡
Conclusion & Impact:In Western Blot evaluations, there was a significant decrease in the expression of NF-κB protein in treatment groups compared to sepsis group.Conclusions: It was observed that Thalidomide and Etanercept had potential effects on the treatment of neonatal sepsis.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to investigate the effect of Thalidomide and Etanercept on inflammation parameters in a neonatal rat sepsis model induced with Lipopolysaccharide (LPS).Materials and methods: Four-week-old male Wistar Albino rats were used in the experiment. LPS (5 mg/kg) was administered to rats as sepsis-inducing agent and two anti-inflammatory drugs, Thalidomide and Etanercept were given intraperitoneally as chemotherapeutic agents. The septic neonatal rats were treated with Thalidomide (0.5 mg/kg), Etanercept (1 mg/kg), and a combination of the two. All therapeutic agents were injected half an hour after injecting LPS. It took 24 h to perform the entire experiment. Whereupon, liver tissues of the animals were removed, presepsin of liver tissue and NF-κB levels were measured by ELISA analysis and NF-κB protein expression levels were determined by Western blotting.Results: A significant increase was detected in presepsin and NF-κB levels in LPS group compared to sham and treatment groups. In Western Blot evaluations, there was a significant decrease in the expression of NF-κB protein in treatment groups compared to sepsis group.Conclusions: It was observed that Thalidomide and Etanercept had potential effects on the treatment of neonatal sepsis.

Özet

Amaç: Bu çalışmanın amacı, Thalidomide ve Etanercept’inLPS ile indüklenmiş neonatal sıçan sepsis modelinde inf lamasyon parametreleri üzerine etkisini araştırmaktır. Yöntem: Çalışmada, dört haftalık erkek Wistar Albino cinsi sıçanlar kullanıldı. Sıçanlara sepsisi indükleyiciajan olarak LPS (5 mg/kg/gün/ip), kemoterapötik ajanolarak ise iki antiinflamatuar ilaç olan Thalidomide veEtanercept intraperitoneal olarak verildi. Septik sıçanlar,tek başına Thalidomide (0.5 mg/kg/gün/ip), tek başınaEtanercept (1 mg/kg/gün/ip) ve iki ilacın kombinasyonuhalinde tedavi edildi. Tüm terapötik ajan enjeksiyon ları, LPS’nin enjeksiyonundan yarım saat sonra verildive toplam deney süresi, 24 saat içinde gerçekleştirildi.Deneysel aşamanın sonunda uygun koşullar altında hay vanlar sakrifiye edildi ve karaciğer dokuları alındı. Kara ciğer dokusundaki presepsin ve NF-κB seviyeleri ELISAanalizi ile ölçüldü, doku NF-κB protein ekspresyon sevi yeleri ise Western blot analizi ile ortaya konuldu. Sonuç: Sham ve tedavi grupları ile karşılaştırıldığındaLPS grubundaki presepsin ve NF-κB düzeylerinde anlamlıbir artış saptanmıştır. Western Blot değerlendirmelerindeise, tedavi gruplarındaki NF-κB protein ekspresyon sevi yelerinde sepsis grubuna göre kıyasla anlamlı bir azalmagözlenmiştir. Tartışma: Thalidomide ve Etanercept’in neonatal sepsisintedavisi üzerinde potansiyel etkileri olduğu gösterilmiştir.

🔖

Cite This Article

SUSAM, S., GÜL, H. F., İLHAN, N., İLHAN, N., BARDAŞ, R. (2022). The effect of specific therapeutic agentson inflammation in sepsis-induced neonatal rats. Türk Biyokimya Dergisi, Cilt: 45 - Sayı: 3, 315–321. https://ajindex.com/articles/620749

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Buttenschoen K, Radermacher P, Bracht H. Endotoxin elimination in sepsis: Physiology and therapeutic application. Langenbecks Arch Surg 2010;395:597–605
  2. Kim M-J, Kim SS, Ko JH, Moon Yl, Park K-J, An HJ, et al. Effects of Shiranuhi flower extracts and fractions on lipopolysaccharideinduced inflammatory responses in murine RAW 264.7 cells. Turk J Biochem 2018;43:375–84
  3. Davies B, Cohen J. Endotoxin removal devices for the treatment of sepsis and septic shock. Lancet Infect Dis 2011;11:65–71
  4. Grunwald U, Krüger C, Westermann J, Lukowsky A, Ehlers M, Schütt C. Anenzyme-linked immunosorbent assay for the quantification of solubilized CD14 in biological fluids. J Immunol Methods 1992;55:225–32
  5. Yu H, Zeng Y, Zhou C. Research progress of presepsin in sepsis diagnosis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2017;29:756–59
  6. Mussap M, Noto A, Fravega M, Fanos V. Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers. J Matern Fetal Neonatal Med 2011;24:12–14
  7. Yaegashi Y, Shirakawa K, Sato N, Suzuki Y, Kojika M, Imai S, et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother 2005;11:234–38
  8. Faix JD. Presepsin – the new kid on the sepsis block. Clin Biochem 2014;47:503–4
  9. Liu B, Yin Q, Chen YX, Zhao YZ, Li CS. Role of Presepsin (sCD14- ST) and the CURB65 scoring system in predicting severity and outcome of community acquired pneumonia in an emergency department. Respir Med 2014;108:1204–13
  10. Masson S, Caironi P, Spanuth E, Thomae R, Panigada M, Sangiorgi G, et al. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial. Crit Care 2014;18:R6
  11. Malíčková K, Koucký M, Pařízek A, Pelinková K, Brodská H, Hájek Z, et al. Diagnostic and prognostic value of presepsin in preterm deliveries. J Matern Fetal Neonatal Med 2015;28:1032–37
  12. Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Murai A, et al. Presepsin as a powerful monitoring tool for the prognosis and treatment of sepsis: a multicenter prospective study. J Infect Chemother 2014;20:30–34
  13. Yang L, Li D, Zhuo Y, Zhang S, Wang X, Gao H. Protective role of liriodendrin in sepsis-induced acute lung injury. Inflammation 2016;39:1805–13
  14. Majumdar S, Lamothe B, Aggarwal BB. Thalidomide suppresses NF-kappaB activation indu